The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...

The agency authorized Novavax to start a Phase 3 trial of its combination shot after the company “satisfactorily” addressed ...

The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ:MNDY ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine ...

The FDA has cleared the company to begin enrolling the planned Phase 3 trial following the determination that Novavax satisfactorily addressed all clinical hold issues. Novavax will be working with ...

Novavax ends UK COVID-19 vaccine contract, agreeing to repay $123.8M in quarterly installments by 2027 as part of settlement. Vandana Singh Robinhood, Novavax, Phunware, Lucid Group, And Tesla ...

Jefferies analyst Roger Song said motor neuropathy was not a side effect seen in any older trials of Novavax's shots. Still, the pause fueled investor worries over the company's growth as its ...

Novavax (NVAX) has been one of the most searched ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to ...

Roger Song has given his Buy rating due to a combination of factors that, despite current challenges, present potential upside for Novavax. The company is dealing with a clinical hold on its CIC ...